Linked Life Data

17764939

Source:http://linkedlifedata.com/resource/pubmed/id/17764939

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-11-6
pubmed:abstractText
The most recent Oxford Overview analysis shows that tamoxifen remains a highly effective adjuvant endocrine therapy with continuing benefit for at least 15 years. The aromatase inhibitors (AIs) achieve a further small reduction in recurrence in postmenopausal women either as first-line treatment or sequentially after 2-3 years tamoxifen but so far usually without survival benefit. Differences in side effects are minor and specifically there is no evidence for significant differences in cardiovascular side effects. Extended adjuvant therapy with an AI after 5 years tamoxifen gives important additional protection to women with higher risk cancers. The relative benefits of first-line vs. sequential AIs after 2-3 years tamoxifen await the outcome of current trials. The major outstanding questions include duration of endocrine therapy, the value of ovarian suppression in premenopausal women in addition to other treatments, and the selection of patients who require endocrine therapy alone without additional chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0960-9776
pubmed:author
pubmed:issnType
Print
pubmed:volume
16 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S4-9
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
pubmed:affiliation
Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK. ian.smith@rmh.nhs.uk
pubmed:publicationType
Journal Article, Review